Clinical TrialJun 8, 2026, 04:02 PM
Polyrizon Secures 3 Key US Clinical Sites for NASARIX™ Trial
AI Summary
Polyrizon Ltd. announced it has secured agreements with two additional U.S. clinical sites, bringing the total to three major contracted sites for its upcoming NASARIX™ (PL-14) clinical study. These sites are considered the largest and most strategically important, expected to drive high patient enrollment for the multi-center trial evaluating the NASARIX™ Allergy Blocker for seasonal allergic rhinitis. The company believes this rapid expansion of its clinical site network positions it strongly for efficient patient recruitment and timely study execution.
Key Highlights
- Polyrizon secured agreements with 2 additional U.S. clinical sites.
- Total of 3 major U.S. clinical sites now contracted for NASARIX™ trial.
- These sites are expected to contribute the highest rates of patient enrollment.
- The NASARIX™ (PL-14) study will evaluate an allergy blocker for seasonal allergic rhinitis.
- The multi-center trial plans for up to 5 clinical sites in the U.S.
Price Impact
More from PLRZ